Horizon Therapeutics PLC (HZNP)
64.98
-2.90 (-4.28%)
USD |
NASDAQ |
Oct 07, 16:00
62.97
-2.02 (-3.10%)
After-Hours: 17:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 14.97B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -39.98% |
| Valuation | |
| PE Ratio | 20.06 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.027 |
| Price to Book Value | 3.027 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5191 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 65.57% |
News
Headline
Wire
Time (ET)
SA Breaking News
10/07 09:12
Yahoo
10/06 08:00
Business Wire
10/02 11:15
MT Newswires
09/29 10:44
Yahoo
09/26 06:59
Yahoo
09/21 08:04
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/03/2022* | -- | Results | Q3 2022 | -- | 1.05 | -- | |
| 11/03/2022* | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | 1.07 | 1.33 | -19.36% | |
| 08/03/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | 1.34 | 1.14 | 17.44% | |
| 05/04/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/01/2022 | -- | Results | Q4 2021 | 1.41 | 1.35 | 4.81% | |
| 03/01/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States. |
| URL | https://www.horizontherapeutics.com |
| Investor Relations URL | https://ir.horizontherapeutics.com |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 03, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 06, 2022.
Fundamentals
| Revenue (TTM) | 3.813B |
| Total Expenses (TTM) | 2.909B |
| Net Income (TTM) | 764.96M |
| Total Assets (Quarterly) | 8.853B |
| Total Liabilities (Quarterly) | 3.908B |
| Shareholders Equity (Quarterly) | 4.946B |
| Cash from Operations (TTM) | 1.415B |
| Cash from Investing (TTM) | -231.85M |
| Cash from Financing (TTM) | -91.16M |
Ratings
Profile
Edit
| Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States. |
| URL | https://www.horizontherapeutics.com |
| Investor Relations URL | https://ir.horizontherapeutics.com |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 03, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| JCNIX | 257.61M USD | 5.99% |
| PJP | 11.50M USD | 3.74% |
| HQL | 14.46M USD | 3.69% |
| HQH | 32.81M USD | 3.54% |
| FBIOX | 115.16M USD | 2.28% |
| DBMYX | 51.20M USD | 1.85% |
| THQ | 14.65M USD | 1.65% |
| ATHGX | 76.27M USD | 1.60% |
| JMGQX | 111.18M USD | 1.43% |
| NUGO | 36.27M USD | 1.40% |
| XBI | 75.73M USD | 1.07% |
| FSMAX | 97.35M USD | 0.30% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| HZNP Tweets |